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Background: Viral load (VL) testing is recommended for monitoring people on ART. The National Health Labo-
ratory Service (NHLS) in South Africa conducts >5million laboratory-based VL tests but faces challenges with
specimen integrity and results delivery. Point-of-care (POC) VL monitoring may improve VL suppression
(VLS). We assessed the cost-effectiveness of different strategies for POC testing in South Africa.
Methods: We developed a cost-outcome model utilizing NHLS data, including facility-level annual VL vol-
umes, proportion with VLS, specimen rejection rates, turn-around-time, and the cost/test. We assessed the
impact of adopting POC VL technology under 4 strategies: (1) status-quo; (2) targeted POC testing at facilities
with high levels of viral failure; (3) targeted POC testing at low-performing facilities; (4) complete POC adop-
tion. For each strategy, we determined the total cost, effectiveness (expected number of virally suppressed
people) and incremental cost-effectiveness ratio (ICER) based on expected (>10%) VLS improvement.
Findings: Existing laboratory-based VL testing costs $126m annually and achieves 85.2% VLS. Strategy 2 was
the most cost-effective approach, with 88.5% VLS and $40/additional person suppressed, compared to the sta-
tus-quo. Should resources allow, complete POC adoption may be cost-effective (ICER: $136/additional person
suppressed), requiring an additional $49m annually and achieving 94.5% VLS. All other strategies were domi-
nated in the incremental analysis.
Interpretation: Assuming POC VL monitoring confers clinical benefits, the most cost-effective strategy for POC
adoption in South Africa is a targeted approach with POC VL technologies placed at facilities with high level
of viral failure.
Funding: Funding support from the Bill & Melinda Gates Foundation.
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The World Health Organization (WHO) recommends viral load
testing for monitoring persons living with HIV (PLHIV) on ART [1].
However, providing viral load monitoring to the millions of PLHIV inHIV care remains challenging in resource-limited settings. In South
Africa, the National Health Laboratory Service (NHLS) is the largest
diagnostic pathology service provider and provides laboratory and
related public health services to over 80% of the population. In 2018,
the NHLS operated a highly centralized national viral load network
that conducted more than five million viral load tests at 16 laborato-
ries. Despite this wide network, the system faces challenges regard-
ing specimen integrity, and result delivery, which can cause delays in
clinical decision making and timely adherence counseling provision
[2]. Currently, only 69% of PLHIV on ART in South Africa receive viral
Research in Context
Evidence before this study
We searched PubMed for studies published up to 15 July 2020
with the search terms “point-of-care” and “cost-effectiveness”
and “viral load” with no language or date restrictions. Relevant
studies have assessed POC diagnostic accuracy, costs, cost-
effectiveness, and clinical outcomes relative to centralized test-
ing. We did not find studies assessing POC testing performance
in low throughput settings or analyses of the cost-effectiveness
of POC VL testing relative to conventional centralized labora-
tory testing at scale; nor did we find studies providing deci-
sion-makers with information on how to incorporate POC
instruments into a national viral load monitoring program such
that instrument utilization and outcomes are optimized.
Added value of this study
To our knowledge, this is the first paper to assess the feasibility
of different adoption strategies for POC viral load monitoring
on a national scale. This analysis is novel in that it incorporates
both costs and outcomes and uses facility-level data to match
viral load demand to equipment capacity in order to minimize
costs. This study can provide insight to resource-limited set-
tings in implementing POC viral load adoption strategies.
Implications of all the available evidence
POC viral load testing has been demonstrated to improve the
proportion of people virally suppressed on ART. Used strategi-
cally, POC can be an important complementary strategy to con-
ventional centralized testing in a national viral load program
and can improve access for harder to reach facilities/popula-
tions and/or improve outcomes.
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ule [3]. Timely viral load testing is the first essential step to detecting
a person with an unsuppressed viral load and to implement the
appropriate clinical action (adherence counseling and/or switch to
second-line ART) [4]. Persons with long-term unsuppressed viral
loads who do not receive appropriate clinical action are at risk for
poorer health outcomes and/or onward HIV transmission [5].
Improving viral load testing coverage in accordance with national
guidelines is critical to aid in South Africa’s achievement of high lev-
els of viral suppression to meet the last 95% of UNAIDs ambitious HIV
targets.
Point of care (POC) viral load technologies can be used to achieve
two (non-mutually exclusive) primary goals: (1) increasing viral load
access (e.g. bringing viral load testing to remote areas or to patients
who have not typically accessed viral load testing), and (2) improving
patient outcomes by providing an immediately actionable test result
and decreasing the amount of time patients spend virally unsup-
pressed. A recent trial conducted in South Africa found that POC viral
load testing improved patient retention in care by 7¢7% (8592%) and
viral suppression (<200 copies/ml) by 12¢4% at 18 months post treat-
ment initiation for patients on ART who accessed a viral load through
POC (93% viral suppression) as compared to standard centralized
testing (83% viral suppression) [6]. A study in Malawi found that
near-POC viral load testing targeted at patients suspected of treat-
ment failure or returning to care following a previously elevated viral
load, was feasible and consistently enabled prompt clinical action [7].
Another study in Malawi found that POC viral load testing increased
clinically indicated ART regimen switches (86% vs 67%) and reduced
the time to switching (6.8 months vs 9.7 months) [8]. However, thereis a lack of data about whether POC viral load testing adoption in a
clinic-based setting is cost-effective relative to conventional central-
ized laboratory testing in resource-limited settings. Cost-effective-
ness of POC viral load testing adoption strategies are likely to be
influenced by a number of factors including instrument utilization,
equipment cost, instrument placement, test accuracy in decentralized
settings, and impact on patient clinical outcomes [9,10]. We sought to
assess the cost-effectiveness of different adoption strategies for POC
HIV viral load monitoring to improve patient outcomes in South
Africa.
2. Methods
We developed a geospatial cost-outcome model utilizing existing
aggregate data from NHLS in order to assess the cost per outcome for
the entire system taking into account facility-level heterogeneity. We
used data for all facilities in South Africa that send blood specimens
to centralized NHLS laboratories for viral load testing for the 2018
calendar year, including annual viral load volumes; suppression rates
(<1000 copies/ml); specimen rejection rates; turn-around time (TAT)
measured from when the specimen is registered at the laboratory
until the results are reviewed; and the cost per viral load test by test-
ing platform. We considered different POC adoption strategies: inte-
grating and leveraging ‘additional capacity’ currently available on
instruments in-country; targeting POC test use for certain facilities or
to certain patient populations within facilities; and/or prioritizing
POC instrument placement at facilities that perform poorly in terms
of specimen rejection and clinical action delays.
We included different instruments on the market that perform
POC viral load tests; the Xpert HIV-1 Viral Load (Cepheid, Sunny-
vale, USA) (“Xpert”) and the newly available m-PIMATM HIV-1/2 Viral
Load (Abbott, USA) (m-PIMA)[11]. Whilst the NHLS currently uses 4,
16 or 80 module Xpert instruments for tuberculosis diagnosis, these
instruments are located at laboratories and have not been used in a
POC setting, nor have they been used for HIV viral load testing in
South Africa. Abbott’s m-PIMATM offers the advantage of being better
suited to operating in a true POC setting operated by lay healthcare
workers, but is typically more costly than the Xpert (Table 2) and
only comes in a single module instrument [11]. As such, we assessed
the impact of the adoption of these two validated viral load POC tech-
nologies, the Xpert and m-PIMA, under four strategies (Table 1).
The facility selection criteria are outlined in Table 1. All facilities
that currently send viral load specimens for testing at centralized lab-
oratories were included in Strategy 1 (“Status quo”) and 4 (“All POC”).
For the other two strategies, we included health facilities that would
be considered suitable candidates for POC placement within the con-
text of the HIV program: clinics, community health centers and dis-
trict hospitals that provide out-patient services to HIV patients and
that do not generally have onsite laboratories. Strategy 2 targeted
only facilities that reported low viral suppression rates and/or high
numbers of unsuppressed viral loads (“Unsuppressed targeted”). For
strategy 3, POC instruments were allocated to facilities that per-
formed the worst on three measures, (1) low viral suppression, (2)
long TAT, 3) and high specimen rejection rates, until 15% of viral load
testing volumes were covered (“Combination targeted”). In addition,
in order to minimize costs, targeting involved identifying candidate
facilities that had sufficient viral load volumes (approximately 47
tests per POC device per day) such that instrument capacity would be
maximized.
2.1. Capacity and allocation of POC instruments
We assumed the Abbott m-PIMATM could perform between 4 and
7 viral load tests per day with each test taking less than 70 min to
conduct [12]. The testing capacity for the Cepheid Xpert was deter-
mined assuming a 7-h day, 90 min per test multiplied by the number
Table 2
Viral load testing costs*.
Technology Cost per viral load test Sources
USD USD (range)
Abbott m-PIMATM 37¢68 29¢5145¢85 NHLS costing[14]
Cepheid Xpert II 28¢33 25¢1143¢16 Global Fund procurement [15]
and NHLS costingIV 25¢40 23¢3534¢37
XVI 23¢98 22¢5030¢11
Centralized testing 24¢46 NHLS price list
* Costs reported in 2019 USD using average monthly exchange rate for 2019.
www.resbank.co.za.
Table 1
Strategy facility selection criteria.
Strategies Description Selection criteria
1. Status quo All viral load specimens are sent for centralized testing. All facilities in South Africa that currently send viral load specimens to
centralized laboratories
2. Unsuppressed targeted Targeted POC for patients suspected of viral failure at facilities with
low suppression rates/high numbers of unsuppressed viral loads
Facilities with at least one unsuppressed viral load expected daily or
facilities with the lowest viral suppression rates (less than 80% 
quintile 4 and 5) but at least 4 viral loads expected per day were
selected for this strategy. Only primary healthcare facilities and dis-
trict level hospitals were included.
3. Combination targeted POC coverage at facilities with a combination of low suppression rates,
and high rejection rates and TAT
Facilities were divided into quintiles according to their viral load spec-
imen rejection rates, viral load suppression rates, and TAT. Facilities
were scored based on their total quintile score, and sorted in
descending order. The lowest performing facilities according to
these indicators (low viral suppression, long TAT and high specimen
rejection rates) were selected for POC coverage until 15% of national
viral load volumes were covered* Only primary healthcare facilities
and district level hospitals were included.
4. All POC A complete switch from centralized to POC testing All facilities in South Africa that currently send viral load specimens to
centralized laboratories were allocated POC instruments according
to their viral load volumes.
* 15% coverage is typically required to ensure the lowest cost per test in pricing agreements with volume commitments.
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instruments were allocated to facilities and matched as closely as
possible to the viral load volumes at the facility and the capacity of
the POC instruments. In strategy 3, new facilities were allocated POC
instruments until 15% of national viral load volumes were covered;
strategy 4 involved deploying instruments at facilities until each
facility’s viral load volume was met by POC capacity. Strategies 3 and
4 had mixed-technology POC strategies, whereby either m-PIMA
and/or Xpert POC instruments were allocated depending on the vol-
ume of viral loads required at the facility. Anecdotal evidence from
NHLS suggested that at low volumes, the m-PIMA was easier to oper-
ate by lay staff in health facilities. For strategy 3 and 4, m-PIMA was
first allocated to facilities with less than 7 expected daily viral loads,
and then Xperts were allocated and their capacity matched to the
daily viral load volumes at the selected facilities Strategy 2 differed
slightly from the other two POC strategies in that only patients sus-
pected of being unsuppressed (measured using the number of
expected unsuppressed viral loads) were tested using POC. Any addi-
tional instrument capacity was used to test suspected suppressed
viral loads and excess viral loads were sent to the centralized labora-
tory for testing. Differences in the total POC tests conducted by
mPIMA or Xpert sub-strategies is driven by differences in the POC
instrument capacity. In strategy 2, given the smaller POC volumes
based on the number of expected unsuppressed viral loads a day, a
mixed technology POC strategy was not considered.
2.2. Cost analysis
For centralized viral load testing, we used the NHLS ‘charge’ price
(for which we had permission to use) from 2017 (inflated to 2019).
The price is all-inclusive of consumables, specimen transport, testing
and result delivery. The m-PIMA cost is based on estimates from the
NHLS with the upper-bound based on an outright instrument pur-
chase arrangement with low test volume commitment and the
lower-bound on an instrument lease arrangement with the largest
volume commitment [14]. Building on the approach used by Simeon
et al., Cepheid Xpert viral load test costs were based on instrument
procurement and reagent prices as reported by the Global Fund and
the range reflects low to high volume commitments for reagent pri-
ces as well as low to high instrument capacity utilization [15]. Both
the costs for m-PIMA and Xpert included other costs sourced from
NHLS: staff costs associated with running samples, interpreting and
recording results; the consumables used per test; the training of the
staff nurse; a laboratory manager’s oversight time; the cost of a POCcoordinator that oversees the administrative costs of running a POC
program at scale, support equipment (e.g. micro centrifuge), support
travel and external quality assessment [14]. All costs are reported in
2019 US dollars (Table 2).
2.3. Cost-effectiveness and budget impact analysis
For each strategy and POC technology, we determined the total
cost, effectiveness (defined as the total expected number of people
with suppressed viral load (<1000 copies/ml)) and incremental cost-
effectiveness ratio (ICER) based on an expected improvement in sup-
pression rates from POC adoption ($ amount per additional person
suppressed). A cost-effectiveness frontier was created to determine
the strategies that are more likely to be considered cost-effective at
different levels of budget availability.
The expected improvement in suppression from POC adoption
were based on the results from the South African-based Simplifying
HIV TREAtment and Monitoring (STREAM) POC viral load trial[6].
Using a suppression threshold of <1000 copies/ml, the proportion of
patients virally suppressed was expected to improve by 10¢8% for
POC viral load tests compared to centralized testing, and by 62% for
those previously unsuppressed (the percent change between POC
and standard of care for those who were unsuppressed at baseline
and who became suppressed, using the threshold of 1000 copies/ml)
(Strategy 2). Current levels of viral suppression were adjusted by
these factors and multiplied by the number of expected viral load
tests to determine the new number of expected people with sup-
pressed viral loads.
The national total cost for each strategy was calculated by esti-
mating the viral load volumes to be tested on each platform (central-
ized, Xpert and m-PIMA). The average utilization of the platform
given its capacity was calculated to determine the associated cost of
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lowest costs for the highest utilization and high costs for the lowest
utilization. Costs were reported for a 1-year time period and included
financial costs from the provider’s perspective. All costs included in
the analysis are outlined above and reported in Table 2. Additional
economic costs and the health and cost impact of different strategies
on HIV transmission were not included in this analysis.2.4. Sensitivity analysis
To assess the robustness of our model and conclusions, we con-
ducted a multiple one-way sensitivity analysis varying the cost per
POC viral load test (reducing the cost of m-PIMA to the costs deter-
mined for Xpert II and reducing Xpert reagent costs to ensure cost-
neutrality with the status-quo) and varying the effectiveness of POC
viral load testing in improving viral suppression (+/50% in the
absence of additional trial evidence) and assuming a less than perfect
ability of the clinic to target those who are unsuppressed (from 100%
to 10% which is conservative given that past viremia is predictive of
future viremia [4]). Changing the ability to target a patient with vire-
mia does not change the total number of tests being conducted on
POC. It rather assumes that clinicians are only able to target one out
of every ten patients who are unsuppressed for POC testing, and that
the remaining nine tests are done on patients that do not have vire-
mia if there is sufficient POC capacity (or else referred for centralized
testing). This changes the potential effectiveness of POC as the effec-
tiveness of POC is more pronounced if the patient is initially unsup-
pressed. To assess the interaction of these uncertain parameters, we
additionally conducted a probabilistic sensitivity analysis through
1000 Monte Carlo simulations. For each parameter in the one-way
sensitivity analysis (excluding the threshold analysis on the Xpert
reagent costs), we sampled from a uniform distribution between the
high and low value.2.5. Ethics
The National Priority Programmes of NHLS currently holds blan-
ket ethics approval (HREC M160978) for retrospective analyses of
laboratory data through the Integrated Laboratory Data Analysis for
Care (ILDAC) program. This blanket approval covers projects that
make use of existing, routinely collected laboratory data relevant toTable 3
Distribution of facilities and viral load volumes.
Viral load daily test volume category Number of facilities % facilities Ave
Less than 1 per day 1088 26% 116
Between 1 and 4 per day 1567 37% 558
Between 4 and 7 per day 634 15% 132
Between 7 and 14 per day 605 14% 239
Greater than 14 per day 322 8% 575
Total 4216 100% 122
Table 4
Facility characteristics at baseline for each strategy.
Strategies Number of facilities Mean daily viral load volumes (SD) Me
Centralized POC
1. Status quo 4216 0 4¢9 (7¢0) 0¢7
2. Unsuppressed targeted 3353 863 13¢0 (9¢1) 1¢9
3. Combination targeted 3260 956 3¢3 (4¢3) 0¢7
4. All POC 0 4216 4¢9 (7¢0) 0¢7the national control programs. Only aggregate facility-level count
data were used for this analysis.
2.6. Role of the funding source
This work was supported by the Bill & Melinda Gates Foundation
through the Innovation in Laboratory Engineered Accelerated Diag-
nostics investment (grant number OPP1171455). The funders had no
role in the study design, data collection and analysis, decision to pub-
lish, or preparation of the manuscript. The authors’ views expressed
in this publication do not necessarily reflect the views of the Bill &
Melinda Gates Foundation.
3. Results
We included 4216 healthcare facilities in the analysis that send
over 5.1 million specimens for viral load testing at centralized labora-
tories each year. Most facilities (63%, N = 2655) have less than four
specimens per day that need to undergo viral load testing and con-
tribute a fifth of annual viral load volumes. Just 8% (N = 322) of facili-
ties contribute over a third of annual viral load volumes and send on
average more than 14 viral load specimens to centralized laboratories
for testing each day (Table 3).
Table 4 presents descriptive statistics for facilities allocated to
each strategy at baseline, prior to POC adoption. Both strategy 1 and
4 covered all 4216 facilities in the analysis. At baseline in these facili-
ties the mean daily viral load volumes per facility for the full sample
was 4¢9 with a mean number of 0¢7 unsuppressed viral loads
expected per day per facility (Table 4). The mean specimen rejection
rate was 5% and the mean TAT was 60 h. Strategy 2 targeted higher
volume facilities, specifically targeting facilities that expect to test
more than 1 unsuppressed viral load/day  a mean of 1¢9 per facility
per day. Lastly, strategy 3, which targeted low-performing facilities,
had, at baseline, lower viral load volumes (3¢3 per facility per day),
higher TAT (87 h), higher specimen rejection rates (8%) and higher
unsuppressed rates (26% versus 17%).
The centralized network (strategy 1) costs $126 million annually
with viral load suppression of 85¢2% (Table 5). Strategy 2 (targeted
testing) using the Xpert increased viral suppression by 3¢3 percentage
points and was considered highly cost-effective at $40 per additional
person suppressed compared to the centralized network, requiring














(1¢1) 5% (6%) 60 (39)
Table 5
Health and economic outcomes of point of care adoption strategies.
Strategy Description Technology % Viral load volumes tested by platform Total cost (2019 USD) Total number
suppressed (%)
ICER ($/additional
person suppressed)m-PIMA Xpert Centralized
1 Status-quo Centralized 0% 0% 100% $125,802,848 4,382,475 (85¢2%) -
2 Unsuppressed targeted* Xpert only 0% 34% 66% $132,516,289 4,548,682 (88¢5%) $40
2 Unsuppressed targeted * m-PIMA only 27% 0% 73% $132,864,944 4,517,130 (87¢8%) dominated
3 Combination targeted** Xpert only 0% 15% 85% $136,218,447 4,447,944 (86¢5%) dominated
3 Combination targeted** mix 13% 2% 85% $139,751,552 4,447,944 (86¢5%) dominated
3 Combination targeted** m-PIMA only 15% 0% 85% $142,317,674 4,400,744 (86¢5%) dominated
4 All POC mix 36% 64% 0% $174,505,308 4,857,683 (94¢5%) $136
4 All POC Xpert only 0% 100% 0% $180,661,135 4,857,683 (94¢5%) dominated
4 All POC m-PIMA only 100% 0% 0% $235,769,172 4,857,683 (94¢5%) dominated
* Targeted to facilities with highest number of virally unsuppressed patients.
** Targeted to facilities that have a combination of low viral suppression, long turnaround time and high specimen rejection rates.
Fig. 1. Cost-effectiveness frontier. All strategies above the cost-effectiveness frontier (the gray line) are considered either more costly and less effective, or more costly and less cost-
effective.
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with an ICER of $136 per additional person suppressed compared to
the next most cost-effective strategy, Strategy 2. The all-POC strategy
would require an additional $48¢7 million annually compared to the
centralized network, with viral load suppression of 94.5%. As shown
by the cost-effectiveness frontier (Fig. 1), all other strategies were
found to be either more costly and less effective or more costly and
less cost-effective (i.e. dominated) in the incremental analysis.
3.1. Sensitivity analyses
When assuming POC viral load resulted in either lower/higher
levels of viral suppression than baseline (reduction of 50% or an
improvement of 50%), ICERs proportionally increased/decreased from
$40 to $81/$27 for strategy 2 (Xpert-only) and from $136 to $588/$77
per additional person suppressed for strategy 4 (technology mix).
Assuming less than perfect targeting in strategy 2 (only one out of
every ten unsuppressed patients will be targeted for POC testing)increased the ICER marginally from $40 to $42 (Table 6). Neither of
these changed the results regarding the optimal strategy for imple-
mentation.
Assuming a lower cost per viral load test on m-PIMA using base-
line cost of a viral load test on Xpert II (cost reduction of 633%
depending on utilization), from a current cost of $37¢68
($29¢51$45¢85) to a new cost of $28¢33 ($25¢11$43¢16), changed
the order of the cost-effectiveness of the POC adoption strategies for
strategy 2. Strategy 2 remained the least costly after the centralized
strategy, but the m-PIMA sub-strategy was added to the cost-effec-
tiveness frontier with an ICER of $7 per additional person suppressed.
The order of the remaining strategies remained the same, but the
strategies that used m-PIMA technology became less costly. A reduc-
tion in the Xpert reagent cost of 30% (from $14.75 to $11.40) ren-
dered strategy 2 cost-neutral with the status-quo.
Strategy 2 (Xpert-only) and Strategy 4 (technology mix) remained
cost-effective in the probabilistic sensitivity analysis of the interac-
tion of uncertainty around m-PIMA costs, POC impact on viral
Table 6
Sensitivity analysis  imperfect targeting strategy 2 (10010%).
Strategy Description Technology Total Cost (2019 USD) Total number suppressed (%) ICER ($/additional person suppressed)
1 Status-quo Centralized $125 802 848 4 382 475 (85.2%) $0
2 Unsuppressed targeted Xpert only $132 516 289 4 548 682 (88.5%) $40
2* Unsuppressed targeted Xpert only $132 516 289 4 541 993 (88.3%) $42
* Sensitivity analysis on strategy 2.
Fig. 2. Probabilistic Sensitivity Analysis  Cost-effectiveness scatter plot. Strategies with m-PIMA technology drives variation in incremental costs in simulation output. Variation in
the effectiveness (number of persons suppressed) is greater for the full POC strategy (strategy 4) versus the partial POC strategies (strategy 2).
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order of the cost-effectiveness of the POC adoption strategies for
strategy 2 changed  the m-PIMA sub-strategy was less costly for a
given level of viral suppression (Fig. 2). All other strategies were
dominated in the incremental analysis.
4. Discussion
Our model-based analysis evaluated the cost and health impact of
implementing various strategies of POC VL testing in South Africa.
Given clinical benefits from improved viral suppression rates due to
POC viral load testing, we find that the most cost-effective strategy
for viral load POC adoption in South Africa is likely a targeted
approach, with POC instruments placed at larger facilities with high
numbers of patients experiencing viral failure. This is projected to
cost $40 per additional person suppressed compared to the central-
ized network. Should resources allow, the all-POC strategy using a
mix of Xpert and m-PIMA may be cost-effective as well. However,
both strategies require an increase in the health expenditure budget,
5¢3% for Strategy 2 and 38¢7% for Strategy 4, which may impact their
affordability. A reduction in reagent prices for the POC tests would
improve affordability at scale. Importantly, should the reagent cost of
Xpert be reduced by 30%, from $14.75 to $11.40, Strategy 2 would be
cost-neutral with the status quo. These findings are particularlyimportant for countries that have already scaled-up viral load pro-
grams, such as South Africa, or have a strong, comprehensive well-
functioning viral load testing network. Critically, for any of these
strategies to be considered cost-effective, patient-level benefit of POC
viral load testing in terms of improved retention or viral suppression
must be observed in routine practice. Reductions in retention/sup-
pression improvements would result in a higher cost per additional
person suppressed, but the annual viral load budget estimates would
remain the same.
The results demonstrate that instrument utilization matters:
higher volume facilities have better instrument utilization and
consequently lower POC costs. The most cost-effective strategy
(strategy 2) was the use of targeted POC at facilities nationally
that expect more than one unsuppressed viral load a day and
where additional instrument capacity is used to conduct viral
load tests on virally suppressed patients. The cost-effectiveness of
strategy 2 is largely driven by the higher volumes at these facili-
ties which allow for improved instrument utilization and conse-
quently lower costs per viral load test. This result might not be
acceptable to health policy makers who are seeking to ensure
equity through extending access to smaller clinics, or to improve
access to patients at low volume clinics with long TAT and high
specimen rejection rates. Sufficient budget for viral load testing
would have to be available to achieve this particular goal.
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[1621], costs [9], cost-effectiveness [10] and clinical outcomes
[6,8,22] relative to centralized testing, but to our knowledge, this is
the first paper that has assessed the feasibility of different adoption
strategies for POC viral load monitoring on a national scale. This anal-
ysis is also novel in that it incorporates both costs and clinical out-
comes and uses facility-level data to match viral load demand to
equipment capacity in order to minimize costs.
There are several limitations to this analysis. Firstly, there may be
benefits of POC viral load testing that extend beyond what is mod-
elled in the present analysis. POC testing allows for more patient-cen-
tered care as patients can receive a blood draw for a viral load test,
even after the transport for the centralized testing has left for the day
[23]. As such, viral load testing access and consequently volumes
may increase with the availability of POC viral load testing, this is par-
ticularly important in countries that have yet to achieve national viral
load coverage. Point-of-care results may also allow faster referral into
more efficient, decentralized models of differentiated ART delivery
[24] and, by improving specimen rejection rates, decrease the time to
a second viral load after rejection and decrease the amount of unsup-
pressed time in the population.
Secondly, we did not consider the polyvalent nature of the
instruments. Additional capacity on the instruments could be
used to conduct other tests  early infant diagnosis, TB diagnosis,
sexually transmitted infections diagnosis, among others. This
would further decrease costs in the POC strategies. Thirdly, we
used a threshold of 1000 copies/ml to determine the benefits of
POC in increasing the number of people on ART who are classified
as suppressed. This approach however does not take into account
the South African guidelines on viral load failure thresholds nor
to the limit of detection of the different platforms. South Africa
has recently adjusted the viral load threshold for detecting viral
failure to >50 copies/ml from 400 copies/ml [25], below the
WHO-recommended 1000 copies/ml threshold. Whilst we used
the WHO threshold to ensure greater comparability with other
low resource settings, the South African program might need to
additionally consider the cost of misclassification of m-PIMA
(with a limit of detection of 314 copies/ml) versus Xpert (limit of
detection of 38 copies/ml) [26,27]. Fourth, we do not take into
account the capacity and ability of certain facilities to adopt POC
testing and incorporate it into clinic operations [28] and we have
assumed that nurses will be able to perform plasma sample proc-
essing and POC testing in routine healthcare facilities [29]. A limi-
tation of the low performing facility strategy is that low
performing facilities might be dysfunctional in ways that will
affect the effective operationalization of POC. Fifth, we have only
evaluated the one-year impact on the national viral load testing
budget. While several POC interventions did not prove to be cost
saving in the short term, they could be cost-effective or possibly
cost saving if prevention of HIV transmission was considered.
Lastly, there may be other, less costly methods to return the
results directly to a patient and possibly confer the same patient-
level benefit as observed in the STREAM POC viral load trial, such
as text result-delivery directly to the patient [30].
Assuming POC viral load testing improves patient viral sup-
pression, the most cost-effective strategy for viral load POC adop-
tion in South Africa is likely a targeted approach, in which POC
are placed in larger facilities with high rates of viral failure. The
results of this analysis are generalizable across a broad number of
countries, in particular countries that have already scaled up their
centralized laboratory systems and are looking to improve access
for the harder to reach facilities and/or improve outcomes. This
methodology can also be adapted to improve laboratory access
for other conditions than HIV, achieve optimal placement of
equipment, and evaluate trade-offs between centralized and
decentralized laboratory testing.Authors’ contributions
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